Literature DB >> 32835761

Oxymatrine ameliorates imiquimod-induced psoriasis pruritus and inflammation through inhibiting heat shock protein 90 and heat shock protein 60 expression in keratinocytes.

Xuechuan Xiang1, Chuyue Tu1, Qiaoyun Li1, Wen Wang1, Xiaoqing Huang2, Zhongqiu Zhao3, Hui Xiong4, Zhinan Mei5.   

Abstract

In this work, we aimed to investigate whether oxymatrine exerts its anti-pruritic and anti-inflammatory efficacy in the imiquimod-induced psoriasis mice and the related mechanism. We established the psoriasis model by applying the imiquimod ointment topically and oxymatrine was injected intraperitoneally as the treatment. The behavior and skin morphology results indicated that oxymatrine inhibits imiquimod-induced pruritus alleviating keratinization of skin and inflammatory infiltration. Moreover, we examined the expression of various indicators and found heat shock protein (HSP) 90 and 60 upregulated in model group, which were reversed in oxymatrine treated groups. Molecular docking and the studies in vivo confirmed that HSP90 and HSP60 participate in the inhibitory effect of oxymatrine on the phenotypes of psoriasis mice. Mechanically, immunofluorescence staining demonstrated that oxymatrine-induced downregulation of HSP90 and HSP60 was mainly in keratinocytes. In vitro results showed that oxymatrine decreases the expression of HSP90 and HSP60 upregulated by TNF-α and IFN-γ in HaCaTs cells and the siRNA mediated HSP90 and HSP60 silencing reverses inflammation inhibited by oxymatrine. Taken together, these results indicate that oxymatrine relieves psoriasis pruritic and inflammation by inhibiting the expression of HSP90 and HSP60 in keratinocytes through MAPK signaling pathway.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemical compounds enlisted in this article: oxymatrine (PubChem CID: 114850).; Heat shock protein 60; Heat shock protein 90; Oxymatrine; Psoriasis

Year:  2020        PMID: 32835761     DOI: 10.1016/j.taap.2020.115209

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

Review 1.  Advances in the Application of Natural Products and the Novel Drug Delivery Systems for Psoriasis.

Authors:  Jin Xie; Shengjie Huang; Haozhou Huang; Xuan Deng; Pengfei Yue; Junzhi Lin; Ming Yang; Li Han; Ding-Kun Zhang
Journal:  Front Pharmacol       Date:  2021-04-21       Impact factor: 5.810

2.  Paeonol Ameliorates Chronic Itch and Spinal Astrocytic Activation via CXCR3 in an Experimental Dry Skin Model in Mice.

Authors:  Wen Wang; Qiaoyun Li; Zhongqiu Zhao; Yutong Liu; Yi Wang; Hui Xiong; Zhinan Mei
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

3.  Full-Length Transcriptome Sequencing Analysis of Differentially Expressed Genes and Pathways After Treatment of Psoriasis With Oxymatrine.

Authors:  Xiaoxiao Xue; Jiayu Yu; Cheng Li; Fang Wang; Yatao Guo; Yongwen Li; Huijuan Shi
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

4.  The exploration of the potential mechanism of oxymatrine-mediated antipruritic effect based on network pharmacology and weighted gene co-expression network analysis.

Authors:  Zhenhui Luo; Tingting Zhao; Mengqin Yi; Tingting Wang; Zhenglang Zhang; Wenbin Li; Na Lin; Shangdong Liang; Alexei Verkhratsky; Hong Nie
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

5.  Oxymatrine Attenuates Osteoclastogenesis via Modulation of ROS-Mediated SREBP2 Signaling and Counteracts Ovariectomy-Induced Osteoporosis.

Authors:  Chao Jiang; Qingliang Ma; Shiyu Wang; Yang Shen; An Qin; Shunwu Fan; Zhiwei Jie
Journal:  Front Cell Dev Biol       Date:  2021-05-31

6.  Xiao-Yin-Fang Therapy Alleviates Psoriasis-like Skin Inflammation Through Suppressing γδT17 Cell Polarization.

Authors:  Xilin Zhang; Xiaorui Li; Youdong Chen; Bingjie Li; Chunyuan Guo; Peng Xu; Zengyang Yu; Yangfeng Ding; Yuling Shi; Jun Gu
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.